Table 39 (abstract P105). 2010 and 2016 improvement criteria after 6, 18 and 24 months of treatment with PDN or PDN + MTX or PDN + CSA (only few examples are reported)
From: Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part one
2010 or 2016 criteria of improvement | PDN | PDN + CSA | PDN + MTX | P values |
|---|---|---|---|---|
N = 47 | N = 46 | N = 46 | ||
N (%) [95%CI] | N (%) [95%CI] | N (%) [95%CI] | ||
Month 6 | ||||
2010 ≥ 20% | 24 (51%) [36–66] | 32 (70%) [54–82] | 33 (72%) [56–84] | 0.023 |
2016 at least minimal | 26 (55%) [40–70] | 34 (74%) [59–86] | 34 (74%) [59–86] | 0.027 |
Month 18 | ||||
2010 ≥ 50% | 20 (42%) [28–58] | 30 (65%) [50–79] | 29 (63%) [47–77] | 0.015 |
2016 at least moderate | 21 (45%) [30–60] | 30 (65%) [50–79] | 30 (65%) [50–79] | 0.020 |
Month 24 | ||||
2010 ≥ 70% | 18 (38%) [24–54] | 26 (56%) [41–71] | 26 (56%) [41–71] | 0.042 |
2016 at least major | 17 (36%) [23–51] | 27 (59%) [43–73] | 27 (59%) [43–73] | 0.012 |